Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 4/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.42 |
| ▸ | MTOR | P42345 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603008 | 0.87 | PIK3CA (0.53) | ITGA2BGBA1PIK3CAPIK3CGMTOR | |
| SCHEMBL4938514 | 0.87 | PIK3CA (0.53) | ITGA2BGBA1PIK3CAPIK3CGMTOR | |
| SCHEMBL1263685 | 0.86 | PTPN1 (0.45) | GBA1PIK3CAPIK3CGMTORGLA | |
| SCHEMBL1263343 | 0.85 | ITGA2B (0.49) | ITGA2BGBA1PIK3CAPIK3CGMTOR | |
| SCHEMBL4604862 | 0.84 | PIK3CA (0.58) | ITGA2BGBA1PIK3CAPIK3CGMTOR | |
| SCHEMBL4604545 | 0.83 | PIK3CA (0.51) | ITGA2BGBA1PIK3CAPIK3CGMTOR | |
| SCHEMBL4604848 | 0.82 | ITGA2B (0.49) | ITGA2BGBA1PIK3CAPIK3CGMTOR | |
| SCHEMBL27701932 | 0.81 | ITGA2B (0.41) | ITGA2B | |
| SCHEMBL4930763 | 0.79 | PIK3CA (0.48) | ITGA2BGBA1PIK3CAPIK3CGMTOR | |
| SCHEMBL1264089 | 0.79 | ITGA2B (0.44) | ITGA2BGBA1PIK3CAPIK3CGGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893063-B2 | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-20090143384-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | ASTRAZENECA UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| CN-101010318-A | 2,4, 6-trisubstituted pyrimidines as Phosphatidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | CN | disclosed |
| EP-1773824-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006005915-A1 | 2, 4, 6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143384-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, PIK3CB, TYMP | ITGA2B 1882/4885GBA1 2705/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.